Hypertension Therapy
Bosentan represents improved approach for pulmonary arterial hypertension treatment
Published in Clinical Trials Week, April 5th, 2004
PAH "is a progressive disease that, without treatment, ultimately results in right heart failure and death," scientists in Ireland explained. "For the majority of patients with advanced PAH, therapy requires cumbersome drug delivery devices with serious side effects."
"Endothelin, a potent endogenous vasoconstrictor, is increased in individuals with PAH," noted D. O'Callaghan and colleagues at University College Dublin. "The development of bosentan, a novel, well-tolerated, orally active endothelin antagonist, has significantly changed the therapeutic approach to PAH."
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2004-04-05)
More Articles from Clinical Trials Week
- HIV/AIDS Therapy
Routine resistance testing can improve ART outcome in experienced patients - Transplant Medicine
Effect of CyA on big ET-1 levels 1 year after OHTx characterized - Breast Cancer
Oncologist calls for new guidelines on early reporting from clinical trials - Breast Cancer
Study demonstrates clear survival benefit of treatment in clinical trials - Cancer Therapy
Renal cancer human trial of phenoxodiol in combination therapy begins - Acute Coronary Syndrome
New study demonstrates the benefits of intensive statin therapy - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
